Logo image of ERAS

ERASCA INC (ERAS) Stock Fundamental Analysis

NASDAQ:ERAS - Nasdaq - US29479A1088 - Common Stock - Currency: USD

1.55  -0.03 (-1.9%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ERAS. ERAS was compared to 563 industry peers in the Biotechnology industry. While ERAS has a great health rating, there are worries on its profitability. ERAS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ERAS has reported negative net income.
ERAS had a negative operating cash flow in the past year.
ERAS had negative earnings in each of the past 5 years.
ERAS had a negative operating cash flow in each of the past 5 years.
ERAS Yearly Net Income VS EBIT VS OCF VS FCFERAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

ERAS has a Return On Assets of -32.17%. This is in the better half of the industry: ERAS outperforms 63.77% of its industry peers.
With a decent Return On Equity value of -38.17%, ERAS is doing good in the industry, outperforming 71.94% of the companies in the same industry.
Industry RankSector Rank
ROA -32.17%
ROE -38.17%
ROIC N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ERAS Yearly ROA, ROE, ROICERAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ERAS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERAS Yearly Profit, Operating, Gross MarginsERAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ERAS has been increased compared to 1 year ago.
Compared to 5 years ago, ERAS has more shares outstanding
ERAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ERAS Yearly Shares OutstandingERAS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ERAS Yearly Total Debt VS Total AssetsERAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 0.92, we must say that ERAS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.92, ERAS is in the better half of the industry, outperforming 67.14% of the companies in the same industry.
ERAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.92
ROIC/WACCN/A
WACCN/A
ERAS Yearly LT Debt VS Equity VS FCFERAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ERAS has a Current Ratio of 9.84. This indicates that ERAS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 9.84, ERAS is in the better half of the industry, outperforming 79.22% of the companies in the same industry.
ERAS has a Quick Ratio of 9.84. This indicates that ERAS is financially healthy and has no problem in meeting its short term obligations.
ERAS's Quick ratio of 9.84 is fine compared to the rest of the industry. ERAS outperforms 79.40% of its industry peers.
Industry RankSector Rank
Current Ratio 9.84
Quick Ratio 9.84
ERAS Yearly Current Assets VS Current LiabilitesERAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

ERAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.84%, which is quite good.
EPS 1Y (TTM)10.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ERAS will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.16%
EPS Next 2Y8.12%
EPS Next 3Y6.99%
EPS Next 5Y11.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERAS Yearly Revenue VS EstimatesERAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ERAS Yearly EPS VS EstimatesERAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERAS. In the last year negative earnings were reported.
Also next year ERAS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERAS Price Earnings VS Forward Price EarningsERAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERAS Per share dataERAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.12%
EPS Next 3Y6.99%

More info and screens

0

5. Dividend

5.1 Amount

ERAS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERASCA INC

NASDAQ:ERAS (5/5/2025, 10:47:49 AM)

1.55

-0.03 (-1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners79.8%
Inst Owner Change-0.02%
Ins Owners7.36%
Ins Owner Change0%
Market Cap439.10M
Analysts85.71
Price Target5.36 (245.81%)
Short Float %10.28%
Short Ratio13.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.16%
Min EPS beat(2)13.03%
Max EPS beat(2)35.3%
EPS beat(4)2
Avg EPS beat(4)-4.84%
Min EPS beat(4)-55.48%
Max EPS beat(4)35.3%
EPS beat(8)6
Avg EPS beat(8)6.16%
EPS beat(12)8
Avg EPS beat(12)-13.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5%
PT rev (3m)5%
EPS NQ rev (1m)7.96%
EPS NQ rev (3m)7.5%
EPS NY rev (1m)6.02%
EPS NY rev (3m)7.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.17%
ROE -38.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.58%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.84
Quick Ratio 9.84
Altman-Z 0.92
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)200.09%
Cap/Depr(5y)425.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
EPS Next Y26.16%
EPS Next 2Y8.12%
EPS Next 3Y6.99%
EPS Next 5Y11.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.65%
EBIT Next 3Y-3.2%
EBIT Next 5YN/A
FCF growth 1Y-6.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.1%
OCF growth 3YN/A
OCF growth 5YN/A